The longterm implications of the Trump Bump; Let’s try again on drug pricing
Endpoints assesses the big biopharma R&D stories of the week, with a little added commentary on what they mean for the industry.
Biopharma investors fall in love with President Trump, for now
In the lead-up to the election, it was abundantly clear that most biotech execs — a well-educated group based largely in Democratic strongholds — clearly sided with Hillary Clinton. Not that they were enthusiastic about their deeply flawed candidate. If anything, the sentiment seemed clearly driven by antipathy for Donald Trump.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
